Abstracts

787 – Timing of Isoniazid Initiation in Pregnancy Among Women Living With HIV and Perinatal Outcomes

Background Isoniazid (INH) as tuberculosis (TB) preventive treatment is routinely offered to pregnant women living with HIV (WLHIV) in Kenya. Yet, safety studies of INH use in pregnancy show inconsistent results and the World Health Organization calls for more robust evaluation of perinatal outcomes following prenatal INH use. Methods We analysed data from an ongoing…

791 – Evaluating Viral Decay Kinetics of Long-Acting Cabotegravir/Rilpivirine in Pregnancy

Background Long-acting cabotegravir plus rilpivirine (LA CAB/RPV) is an effective alternative to oral ART in non-pregnant populations, reducing pill burden and improving adherence. For pregnant individuals unable to tolerate or reliably take oral therapy,  LA CAB/RPV may provide a critical option to achieve and maintain suppression and reduce perinatal HIV transmission. Data in pregnancy are…

792 – LA CAB/RPV in Pregnancy: Bimonthly Dosing in the Setting of Predicted Reduced RPV Exposure

Background Long-acting cabotegravir and rilpivirine (LA CAB/RPV) provides an alternative to daily oral antiretroviral therapy and has shown high effectiveness and acceptability in non-pregnant populations. During pregnancy, physiologic changes can reduce antiretroviral (ARV) drug concentrations. Pharmacokinetic (PK) modeling indicates that adequate CAB exposure is maintained with monthly dosing; however, there is concern that RPV concentrations…

1013 – Trajectory in Syphilis Infection and Reinfection Among People Living With HIV, 2021-2024

Background Syphilis remains a significant global public health challenge, especially among people living with HIV (PLWH), who face a high risk of acquisition and reinfection. While worldwide and regional data show increasing trends, there is limited longitudinal data from Latin American HIV cohorts. This study describes the trajectory of syphilis infection and reinfection by year…

1034 – Real-Life Evaluation of a Molecular Syndromic Panel for Infectious Genital Ulcer Diagnosis

Background Genital ulcer disease (GUD) is commonly caused by sexually transmitted infections (STIs) and typically occurs in genital, anorectal, or perineal areas, with herpes simplex virus (HSV) and Treponema pallidum (TP) being the most frequent pathogens, while Haemophilus ducreyi (HD) and Chlamydia trachomatis serovar L (CT-LGV) occur less often. Recently, mpox has emerged as an…

591 – Regional Differences in HBV Vaccine History and Response in ACTG A5379: Africa, Asia, Brazil, and US

Background As use of long-acting (LA) ART without HBV activity increases, optimizing HBV prevention in PWH is increasingly important. HepB-CpG, an adjuvanted HBV vaccine, has superior immunogenicity to HepB-alum. Understanding regional variation in revaccination outcomes may inform tailored vaccine strategies. Methods BEeHIVe (ACTG5379, PMID 39616603) enrolled PWH from 41 sites in Africa, Asia, Brazil, and…

331 – Subset of People With HIV (PWH) Continue to Have Decay in Intact Proviral DNA During Long-Term ART

Background Factors that affect intact proviral DNA (IPD) decay in PWH receiving antiretroviral therapy (ART) are incompletely understood. We evaluated the effect of age, sex and markers of senescence on IPD decay, and examined individual decay slopes to assess whether there is heterogeneity in IPD changes. Methods Participants with long-term documented HIV suppression continuously followed…

616 – Project Connect: Linkage-to-Care Outcomes for Patients With Hepatitis C in Los Angeles County

Background Hepatitis C remains a major cause of cirrhosis, liver cancer, and hepatitis-related deaths. Chronic infection affects thousands of Los Angeles County residents annually, underscoring the urgent need for treatment. To evaluate Project Connect, we analyzed linkage-to-cure outcomes. Methods Volunteer case-workers contacted Hepatitis C-infected cases reported by a local county health department with three phone…